English
Home > Products > 748788-39-8

China 748788-39-8 Factory

Our commission should be to provide our end users and clients with very best excellent and aggressive portable digital products and solutions for 748788-39-8,CAS NO 748788-39-8,Prucalopride intermediate,Prucalopride advance intermediate,Methyl 4-(acetylaMino)-3-broMo-2, We are looking forward to cooperating with all customers from at home and abroad. Moreover, customer satisfaction is our eternal pursuit.
748788-39-8, Merchandise have been exported to Asia, Mid-east,European and Germany market. Our company has constantly been able to update the goods performance and safety to meet the markets and strive to be top A on stable quality and sincere service. If you have the honor to do business with our company. we will definitely do our very best to support your business in China.

Related Products

Hot Products

  • Dolastatin 10

    Dolastatin 10

    Product Name:Dolastatin 10
    Molecular Formula:C42H68N6O6S
    Molecular Weight:785.09
    CAS Registry Number:110417-88-4
  • 5-Amino-2-chloropyridine

    5-Amino-2-chloropyridine

    Product Name:5-Amino-2-chloropyridine
    Molecular Formula:C5H5ClN2
    Molecular Weight:128.56
    CAS Registry Number:5350-93-6
  • Azasetron hydrochloride

    Azasetron hydrochloride

    Product Name:Azasetron hydrochloride
    Molecular Formula:C17H20ClN3O3
    Molecular Weight;349.81
    CAS Registry Number;123040-69-7
  • Mifepristone

    Mifepristone

    Product Name:Mifepristone
    Molecular Formula:C29H35NO2
    Molecular Weight:429.6
    CAS Registry Number;84371-65-3
  • Iptacopan

    Iptacopan

    Product Name:Iptacopan
    Molecular Formula:C25H30N2O4
    Molecular Weight;422.52
    CAS Registry Number;1644670-37-0
  • 3-Ethoxy-4-Methoxy-alpha-[(Methylsulfonyl)Methyl]-benzeneMethanaMine

    3-Ethoxy-4-Methoxy-alpha-[(Methylsulfonyl)Methyl]-benzeneMethanaMine

    Product Name:3-Ethoxy-4-Methoxy-alpha-[(Methylsulfonyl)Methyl]-benzeneMethanaMine
    Molecular Formula:C12H19NO4S
    Molecular Weight:273.35
    CAS Registry Number:253168-94-4
  • Related Blog
  • Reviews

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    API is fundamental to the modern drug manufacturing process and cutting cost should not be the only criteria that can be applied to the production of an active pharmaceutical ingredient as it can adversely affect human health if the above-mentioned regulations and practices are not followed strictly.

  • Baloxavir marboxil

    Baloxavir marboxil is used to treat flu symptoms caused by influenza virus in people who have had symptoms for no more than 48 hours. Baloxavir marboxil will not treat the common cold. Baloxavir marboxil is for adults and children who are at least 12 years old and weigh at least 88 pounds (40 kilograms).

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • Gilteritinib Fumarate

    Sandoo Pharmaceutica is a professional pharmaceutical intermediates manufacturer. We provide good quality Gilteritinib Fumarate Cas: 1254053-43-4. Welcome and we look forward to your inquiry!

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 748788-39-8

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept